GET DAILY SIGNALSJourney Medical Corporation (DERM): Analyst Targets Center on $14 With Substantial Upside Ahead
Key Takeaways
- The central price target used here is $14, the arithmetic mean of four verified analyst price targets for Journey Medical Corporation (DERM), rounded from an underlying mean of $13.75.
- The latest verified share price of roughly $4.44 implies a required move of about 215% to reach $14 — a very large advance by any standard.
- The four reviewed targets span a range of $13 to $15, with all analysts rating the stock a Buy or equivalent, though the targets sit far above where shares currently trade.
- The strongest supporting factor is the commercial ramp of Emrosi, the company's internally developed oral rosacea treatment, alongside expanding payer reimbursement and a clear path toward profitability.
- The biggest risks are high short interest, execution uncertainty in converting prescriptions into reimbursed revenue, and the substantial gap between the current price and every analyst target.
- For additional context, explore Journey Medical's Major News and Today's Price Move, review its Forecast, and check upcoming Earnings.
- You can also explore Trending AI Robots to see how AI-driven tools scan for opportunities across the market.
Analyst Price Targets and Consensus View
Journey Medical Corporation is a commercial-stage dermatology pharmaceutical company, not an exchange-traded fund. Four current analyst price targets were reviewed to establish the central target: H.C. Wainwright at $13, Alliance Global Partners at $14, Lake Street at $13, and B. Riley at $15. The resulting arithmetic mean is $13.75, rounded to a clean $14 for this analysis, with a range of $13 to $15.
The prevailing view is consistently bullish — data providers characterize the rating as a Strong Buy — but the reasoning is anchored to a single narrative: that Emrosi's prescription growth and improving reimbursement will translate into revenue growth and profitability. Recent revisions reflect this optimism. B. Riley raised its target to $15 from $12, while H.C. Wainwright lifted its target to $13 from $12 in late October 2026. Alliance Global Partners trimmed its target to $14 from $16 in August. Notably, the targets are tightly clustered despite sitting far above the current price, suggesting analysts model substantial upside from execution on the Emrosi launch rather than from a single binary catalyst. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of mid-November 2026, DERM trades near $4.44, near the low end of a 52-week range of roughly $4.25 to $9.56. Reaching $14 from here would require an advance of about 215%, which is a very large move. The stock has pulled back sharply from its January 2026 peak despite improving fundamentals, which is central to why the analyst targets appear disconnected from the current quote.
The path toward the target would require Emrosi to continue scaling prescription volume — roughly 36,000 total prescriptions in the second quarter of 2026, up about 20% sequentially — while the company converts a growing share of those prescriptions into reimbursed, higher-priced revenue. Management has described 2026 as a potential "breakout year," with total second-quarter revenue up 23% year over year to about $18.5 million and adjusted EBITDA turning positive.
What Could Support a Move Toward the Target
- Emrosi launch momentum: Revenue of $8.1 million in the second quarter of 2026, rising prescriptions, and a growing base of over 4,500 unique dermatology prescribers signal durable commercial traction.
- Reimbursement expansion: Contracts with the three largest U.S. group purchasing organizations now provide plan access across more than 169 million covered commercial lives, supporting higher average selling prices over time.
- Profitability inflection: GAAP net loss narrowed to roughly $0.3 million in the second quarter of 2026, with positive EBITDA, suggesting operating leverage as revenue scales.
- Balance sheet: About $25.6 million in cash at mid-2026 provides runway for the commercial build-out.
What Could Prevent the Target From Being Reached
- Gross-to-net and reimbursement friction: Prescription growth has outpaced reported revenue because a meaningful share of scripts still flows through lower-margin co-pay bridging rather than reimbursed coverage.
- Elevated short interest: Roughly 20% of the public float was sold short as of mid-October 2026, reflecting meaningful skepticism about the equity story.
- Valuation gap: With no P/E ratio because the company is not yet consistently profitable, the stock's value depends on projected future cash flows that remain unproven at scale.
- Concentration risk: The investment case rests heavily on a single product in a competitive rosacea market, leaving limited diversification if the launch stalls.
Technical Levels and Market Structure
The 52-week high near $9.56, set in January 2026, stands as a distant but meaningful resistance level; even reaching that prior peak would still leave the stock far short of the $14 target. On the downside, the recent 52-week low near $4.25, touched in early November 2026, is the immediate support level to watch. The stock has been in a sustained downtrend for much of 2026 despite improving fundamentals, a divergence that suggests sentiment and positioning have yet to align with the operating progress. From what I see, this setup warrants close monitoring of volume and momentum indicators.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though the exact horizon varies by firm and is not always disclosed. Key items to watch include the next quarterly earnings report, which the company has scheduled for November 12, 2026, along with guidance on Emrosi prescriptions and revenue-per-script trends. Investors should also track sequential changes in reimbursement mix, gross-to-net adjustments, any new dermatology product launches, analyst target revisions, and shifts in short interest, which can amplify volatility in a small-cap name. I’m watching this closely as the next few quarters will likely clarify the trajectory.
Final Assessment
The $14 target for Journey Medical Corporation is the rounded average of four analyst price targets ranging from $13 to $15, all reflecting a bullish view of the Emrosi launch. Yet the required move — roughly 215% from a price near $4.44 — is very large, and the wide gap between the current quote and every analyst target underscores how much of the thesis depends on flawless commercial execution. Improving prescription trends, expanding reimbursement, and a shift toward profitability are genuine tailwinds, while high short interest, gross-to-net friction, and single-product concentration are substantial obstacles. Whether the stock can close that gap will depend on sustained Emrosi growth and evidence that revenue is catching up to prescriptions, making upcoming earnings and reimbursement data the most important signals to follow.
AI Daily Buy/Sell Signals
For traders monitoring names like DERM, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to traditional research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover opportunities, monitor existing positions, and spot evolving trends more efficiently than manual screening alone. In my view, integrating these signals with fundamental analysis provides a more complete picture for names in transition like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DERM in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
DERM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 35 cases where DERM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DERM's RSI Indicator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where DERM advanced for three days, in 232 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DERM as a result. In 77 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for DERM turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 39 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
The 50-day moving average for DERM moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DERM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for DERM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.929) is normal, around the industry mean (6.379). P/E Ratio (-20.318) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.865) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. DERM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DERM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement